@article{f0dfd80be3884b67bc947160d86dd809,
title = "Patient (pt) Demographics, Treatment Patterns (tx) and Hematologic (heme) Toxicities among pts with HER2− Advanced Breast Cancer (ABC) and BRCA1/2 Mutation(s) (BRCA1/2mut): A Multi-country Real-world (RW) Study",
abstract = " A. Niyazov; K. Lewis; M. Last; A. Rider; B. Arondekar; M.P. Lux ",
author = "Reshma Mahtani",
note = "PARP inhibitors (PARPi) have demonstrated improved progression-free survival compared to chemotherapy (CTX) in clinical trials. Limited information is available on the use of the agents in the RW. We assessed RW tx patterns and heme toxicities in HER2− ABC with BRCA1/2mut in the US and France, Germany, Italy and Spain.",
year = "2020",
language = "American English",
volume = "31",
journal = "Annals of Oncology / European Society for Medical Oncology (ESMO) Breast Conference",
}